Related Experiment Video
Updated: Feb 19, 2026
10:11
Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
Published on: September 27, 2014
37.1K
Virus-Vectored Ebola Vaccines
I V Dolzhikova1, E A Tokarskaya1, A S Dzharullaeva1
1Federal Research Centre of Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya, Ministry of Health, Gamaleya Str. 18, Moscow, 123098, Russia.
Acta Naturae
|November 7, 2017
Summary
Ebola virus disease (EVD) vaccines have advanced significantly, with virus-vectored options showing high efficacy in trials. This review details their development and immune response mechanisms for long-term protection.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Ebola virus disease (EVD) is a severe zoonotic infection with a high fatality rate.
- Over 20 EVD outbreaks have occurred since 1976, including a major epidemic in West Africa (2014-2016).
- Limited vaccine availability hindered early epidemic response, highlighting the need for effective EVD vaccines.
Purpose of the Study:
- To review the technological advancements in EVD vaccine development.
- To focus on virus-vectored Ebola vaccines evaluated in preclinical and clinical trials.
- To examine immune response mechanisms and parameters for long-term EVD protection.
Main Methods:
- Review of scientific literature on Ebola virus disease vaccine development.
- Analysis of preclinical and clinical trial data for virus-vectored vaccines.
- Examination of immunological mechanisms underlying vaccine-induced protection.
Main Results:
- Virus-vectored vaccines have shown significant efficacy in preclinical studies.
- Several EVD vaccine candidates are progressing through clinical trials.
- Understanding immune response pathways is crucial for vaccine effectiveness.
Conclusions:
- Virus-vectored vaccines represent a promising strategy for EVD prevention.
- Continued research into immune responses is vital for optimizing vaccine design.
- Development of licensed EVD vaccines is critical for global health security.
